Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Surface
Oncology
, an immuno-oncology company developing next-generation
immunotherapies that target the tumor microenvironment, today announced
the expansion of the company’s Scientific Advisory Board (SAB) with the
addition of two leading experts in translational cancer immunology.

David Tuveson, M.D., Ph.D. and Jedd D. Wolchok, M.D., Ph.D. will work
with other members of the SAB to help guide the company’s research,
clinical and translational efforts as it works to advance multiple
immuno-oncology product programs through preclinical testing and into
the clinic. Their experience complements that of the existing SAB
members to help Surface to bring next-generation immunotherapies to
people with life-threatening cancer.

We are extremely proud to have enlisted David and Jedd to join our
world-class scientific advisory board,” said Detlev Biniszkiewicz,
Ph.D., President and CEO of Surface Oncology. “As we rapidly advance our
next-generation immunotherapies toward the clinic, the guidance from our
SAB will continue to be critical to our success.”

Dr. Tuveson is a renowned cancer biologist and the Director of the
Cancer Center and Cancer Therapeutics Initiative at Cold Spring Harbor
Laboratory (CSHL), where he also serves as the Roy J. Zuckerberg
Professor of Cancer Research, the Director of the Lustgarten Foundation
Pancreatic Cancer Research Laboratory, and the Lustgarten Foundation’s
Director of Research. In addition to being a highly regarded
translational researcher, Dr. Tuveson is a recognized leader in the
study of the role of the tumor microenvironment in promoting tumor
growth. The focus of his research is pancreatic cancer. He earned his
undergraduate degree in chemistry at M.I.T. and medical and doctoral
degrees at Johns Hopkins University.

Surface Oncology is uniquely positioned to translate emerging knowledge
of the tumor microenvironment into novel approaches for activating an
immune attack on cancer,” said Dr. Tuveson. “I look forward to working
with this dedicated and driven team to help shape new approaches that
could have broad impact on the treatment of cancer patients everywhere.”

Dr. Wolchok is a pioneering clinician-scientist recognized for his
expertise in cancer immunotherapy. He served as principal investigator
on several pivotal clinical trials, including the Phase 3 trial of
ipilimumab for the treatment of melanoma. Dr. Wolchok is the Lloyd J.
Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at
Memorial Sloan Kettering (MSK) Cancer Center; he also serves as Chief of
MSK’s Melanoma & Immunotherapeutics Service, Associate Director of the
Ludwig Center for Cancer Immunotherapy at MSK, and the founding Director
of the Parker Institute for Cancer Immunotherapy at MSK, as well as
Professor of Medicine at Weill Cornell Medical College. An early
proponent of immunotherapy, he established the Immunotherapeutics
Clinical Core at MSK, a specialized Phase 1 outpatient unit that
conducts novel immunotherapy trials. He earned his undergraduate degree
from Princeton, and received both his medical and doctoral degrees from
New York University.

A greater understanding of the tumor microenvironment holds the promise
of unlocking the full potential of immunotherapy and extending its
benefits to far more patients than current approaches,” said Dr.
Wolchok. “I am excited to work with Surface Oncology in support of this
important mission.”

ABOUT SURFACE ONCOLOGY
Surface Oncology is an
immuno-oncology company developing next-generation immunotherapies
targeting the tumor microenvironment. Surface’s novel cancer
immunotherapies are designed to achieve a clinically meaningful and
sustained anti-tumor response, and may be used alone or in combination
with other therapies. The Company has a pipeline of seven novel
immunotherapies, including programs targeting CD47 and CD73, supported
by a broad strategic collaboration with Novartis focused on up to four
next-generation immunotherapies. Headquartered in Cambridge, Mass.,
Surface was founded by Atlas Venture and is also supported by leading
biotechnology venture investors F-Prime Capital Partners, Lilly
Ventures, New Enterprise Associates (NEA) and Amgen Ventures. For more
information, please visit http://www.surfaceoncology.com/.
Follow Surface on LinkedIn.

Contacts

Ten Bridge Communications
Paul Goldsmith, 617-902-0074
Paul@Tenbridgecommunications.com